170 related articles for article (PubMed ID: 14529384)
1. Natural product origins of Hsp90 inhibitors.
Uehara Y
Curr Cancer Drug Targets; 2003 Oct; 3(5):325-30. PubMed ID: 14529384
[TBL] [Abstract][Full Text] [Related]
2. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome.
An WG; Schulte TW; Neckers LM
Cell Growth Differ; 2000 Jul; 11(7):355-60. PubMed ID: 10939589
[TBL] [Abstract][Full Text] [Related]
3. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
Shiotsu Y; Neckers LM; Wortman I; An WG; Schulte TW; Soga S; Murakata C; Tamaoki T; Akinaga S
Blood; 2000 Sep; 96(6):2284-91. PubMed ID: 10979978
[TBL] [Abstract][Full Text] [Related]
4. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs.
Blagosklonny MV
Leukemia; 2002 Apr; 16(4):455-62. PubMed ID: 11960322
[TBL] [Abstract][Full Text] [Related]
5. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Miyata Y
Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
7. Synergistic inhibition of the glucocorticoid receptor by radicicol and benzoquinone ansamycins.
Rosenhagen MC; Young JC; Wochnik GM; Herr AS; Schmidt U; Hartl FU; Holsboer F; Rein T
Biol Chem; 2001 Mar; 382(3):499-504. PubMed ID: 11347901
[TBL] [Abstract][Full Text] [Related]
8. [Heat shock protein 90: novel target for cancer therapy].
Chen Y; Ding J
Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
[TBL] [Abstract][Full Text] [Related]
9. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.
Nimmanapalli R; O'Bryan E; Bhalla K
Cancer Res; 2001 Mar; 61(5):1799-804. PubMed ID: 11280726
[TBL] [Abstract][Full Text] [Related]
10. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy.
Blagosklonny MV; Fojo T; Bhalla KN; Kim JS; Trepel JB; Figg WD; Rivera Y; Neckers LM
Leukemia; 2001 Oct; 15(10):1537-43. PubMed ID: 11587211
[TBL] [Abstract][Full Text] [Related]
11. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
Schulte TW; Neckers LM
Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
[TBL] [Abstract][Full Text] [Related]
12. HSP90 as a new therapeutic target for cancer therapy: the story unfolds.
Maloney A; Workman P
Expert Opin Biol Ther; 2002 Jan; 2(1):3-24. PubMed ID: 11772336
[TBL] [Abstract][Full Text] [Related]
13. Altered states: selectively drugging the Hsp90 cancer chaperone.
Workman P
Trends Mol Med; 2004 Feb; 10(2):47-51. PubMed ID: 15106614
[TBL] [Abstract][Full Text] [Related]
14. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
Neckers L
Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
[TBL] [Abstract][Full Text] [Related]
15. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives.
Maroney AC; Marugan JJ; Mezzasalma TM; Barnakov AN; Garrabrant TA; Weaner LE; Jones WJ; Barnakova LA; Koblish HK; Todd MJ; Masucci JA; Deckman IC; Galemmo RA; Johnson DL
Biochemistry; 2006 May; 45(17):5678-85. PubMed ID: 16634649
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 inhibitors as novel cancer chemotherapeutic agents.
Neckers L
Trends Mol Med; 2002; 8(4 Suppl):S55-61. PubMed ID: 11927289
[TBL] [Abstract][Full Text] [Related]
17. Overview: translating Hsp90 biology into Hsp90 drugs.
Workman P
Curr Cancer Drug Targets; 2003 Oct; 3(5):297-300. PubMed ID: 14529382
[TBL] [Abstract][Full Text] [Related]
18. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
Miyata Y
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
[TBL] [Abstract][Full Text] [Related]
19. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
20. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
